Literature DB >> 22586648

Understanding the lethal variant of prostate cancer: power of examining extremes.

Ana Aparicio1, Christopher J Logothetis, Sankar N Maity.   

Abstract

Small cell prostate carcinoma is a lethal variant of castration-resistant prostate cancer. Beltran and colleagues identified overexpression and amplification of both aurora kinase A (AURKA) and the MYCN proto-oncogene in the small cell prostate carcinomas and propose Aurora kinase A as a potential therapeutic target in this disease subset.
© 2011 AACR.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22586648      PMCID： PMC4133693          DOI： 10.1158/2159-8290.CD-11-0259

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  8 in total

1.  Neuroendocrine prostate cancer xenografts with large-cell and small-cell features derived from a single patient's tumor: morphological, immunohistochemical, and gene expression profiles.

Authors:  Nora M Navone; Sankar N Maity; Ana Aparicio; Vasiliki Tzelepi; John C Araujo; Charles C Guo; Shoudan Liang; Patricia Troncoso; Christopher J Logothetis
Journal:  Prostate       Date:  2010-11-17       Impact factor: 4.104

Review 2.  The MYCN oncogene and differentiation in neuroblastoma.

Authors:  Ulrica K Westermark; Margareta Wilhelm; Anna Frenzel; Marie Arsenian Henriksson
Journal:  Semin Cancer Biol       Date:  2011-08-09       Impact factor: 15.707

Review 3.  Shared and separate functions of polo-like kinases and aurora kinases in cancer.

Authors:  Susanne M A Lens; Emile E Voest; René H Medema
Journal:  Nat Rev Cancer       Date:  2010-11-24       Impact factor: 60.716

4.  Molecular characterization of prostatic small-cell neuroendocrine carcinoma.

Authors:  Nigel Clegg; Camari Ferguson; Lawrence D True; Hugh Arnold; Alec Moorman; Janna E Quinn; Robert L Vessella; Peter S Nelson
Journal:  Prostate       Date:  2003-04-01       Impact factor: 4.104

5.  Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate.

Authors:  Christos N Papandreou; Danai D Daliani; Peter F Thall; Shi-Ming Tu; Xuemei Wang; Adriana Reyes; Patricia Troncoso; Christopher J Logothetis
Journal:  J Clin Oncol       Date:  2002-07-15       Impact factor: 44.544

6.  Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma.

Authors:  Tobias Otto; Sebastian Horn; Markus Brockmann; Ursula Eilers; Lars Schüttrumpf; Nikita Popov; Anna Marie Kenney; Johannes H Schulte; Roderick Beijersbergen; Holger Christiansen; Bernd Berwanger; Martin Eilers
Journal:  Cancer Cell       Date:  2009-01-06       Impact factor: 31.743

7.  PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer.

Authors:  Patrizia Carpinelli; Roberta Ceruti; Maria Laura Giorgini; Paolo Cappella; Laura Gianellini; Valter Croci; Anna Degrassi; Gemma Texido; Maurizio Rocchetti; Paola Vianello; Luisa Rusconi; Paola Storici; Paola Zugnoni; Claudio Arrigoni; Chiara Soncini; Cristina Alli; Veronica Patton; Aurelio Marsiglio; Dario Ballinari; Enrico Pesenti; Daniele Fancelli; Jürgen Moll
Journal:  Mol Cancer Ther       Date:  2007-12       Impact factor: 6.261

8.  Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP).

Authors:  John M Maris; Christopher L Morton; Richard Gorlick; E Anders Kolb; Richard Lock; Hernan Carol; Stephen T Keir; C Patrick Reynolds; Min H Kang; Jianrong Wu; Malcolm A Smith; Peter J Houghton
Journal:  Pediatr Blood Cancer       Date:  2010-07-15       Impact factor: 3.167
  8 in total
  45 in total

Review 1.  Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer.

Authors:  Christopher J Logothetis; Gary E Gallick; Sankar N Maity; Jeri Kim; Ana Aparicio; Eleni Efstathiou; Sue-Hwa Lin
Journal:  Cancer Discov       Date:  2013-06-28       Impact factor: 39.397

2.  The potential of neurotensin secreted from neuroendocrine tumor cells to promote gelsolin-mediated invasiveness of prostate adenocarcinoma cells.

Authors:  Kohei Hashimoto; Yuki Kyoda; Toshiaki Tanaka; Toshihiro Maeda; Ko Kobayashi; Kohsuke Uchida; Hiroshi Kitamura; Koichi Hirata; Taiji Tsukamoto; Naoya Masumori
Journal:  Lab Invest       Date:  2015-01-12       Impact factor: 5.662

Review 3.  Cellular plasticity and the neuroendocrine phenotype in prostate cancer.

Authors:  Alastair H Davies; Himisha Beltran; Amina Zoubeidi
Journal:  Nat Rev Urol       Date:  2018-02-20       Impact factor: 14.432

Review 4.  EMT, stemness and tumor plasticity in aggressive variant neuroendocrine prostate cancers.

Authors:  Rama Soundararajan; Anurag N Paranjape; Sankar Maity; Ana Aparicio; Sendurai A Mani
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2018-07-05       Impact factor: 10.680

Review 5.  Advances in neuroendocrine prostate cancer research: From model construction to molecular network analyses.

Authors:  Xue Shui; Rong Xu; Caiqin Zhang; Han Meng; Jumei Zhao; Changhong Shi
Journal:  Lab Invest       Date:  2021-12-22       Impact factor: 5.662

6.  BRCA2 Alterations in Neuroendocrine/Small-Cell Carcinoma Prostate Cancer: A Case Series.

Authors:  Lynn Symonds; Erik Konnick; Funda Vakar-Lopez; Heather H Cheng; Michael T Schweizer; Peter S Nelson; Colin C Pritchard; Bruce Montgomery
Journal:  JCO Precis Oncol       Date:  2022-07

7.  Neuropilin-2 promotes lineage plasticity and progression to neuroendocrine prostate cancer.

Authors:  Jing Wang; Jingjing Li; Lijuan Yin; Tianjie Pu; Jing Wei; Varsha Karthikeyan; Tzu-Ping Lin; Allen C Gao; Boyang Jason Wu
Journal:  Oncogene       Date:  2022-08-19       Impact factor: 8.756

8.  Multigene Profiling of CTCs in mCRPC Identifies a Clinically Relevant Prognostic Signature.

Authors:  Udit Singhal; Yugang Wang; James Henderson; Yashar S Niknafs; Yuanyuan Qiao; Amy Gursky; Alexander Zaslavsky; Jae-Seung Chung; David C Smith; R Jeffrey Karnes; S Laura Chang; Felix Y Feng; Ganesh S Palapattu; Russell S Taichman; Arul M Chinnaiyan; Scott A Tomlins; Todd M Morgan
Journal:  Mol Cancer Res       Date:  2018-02-16       Impact factor: 5.852

9.  Increased nuclear factor I/B expression in prostate cancer correlates with AR expression.

Authors:  Jagpreet S Nanda; Wisam N Awadallah; Sarah E Kohrt; Petra Popovics; Justin M M Cates; Janni Mirosevich; Peter E Clark; Giovanna A Giannico; Magdalena M Grabowska
Journal:  Prostate       Date:  2020-07-21       Impact factor: 4.104

10.  Transperineal Parallel Biopsy of the Prostate: A New Approach of Tissue Sampling for Precision Medicine.

Authors:  Min Qu; Bijun Lian; Yan Wang; Wenhui Zhang; Feng Zhu; Tao Wang; Xiaodong Yue; Zepeng Jia; Huan Chen; Husheng Li; Jing Li; Xu Gao
Journal:  Int J Gen Med       Date:  2021-05-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.